Accessibility Menu
GH Research logo

GH Research(NASDAQ) GHRS

Market Cap$1.92BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)+45%
5 Year+31%
1 Year+102%
1 Month-0%
Premium Feature
Moneyball Superscore
54/100
$27.95
-2.44%
-0.70Today
After hours$27.87-$0.08 (-0.29%)
GH Research last closing stock price
MetricPriceDate
Last closeUSD 27.942026-08-28
GH Research stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.38%USD 28.332026-08-21
1 month-0.14%USD 27.982026-07-29
3 month+16.47%USD 23.992026-05-29
Year to date+120%USD 12.702025-12-31
1 year+101.88%USD 13.842025-08-28
3 year+141.9%USD 11.552023-08-29
5 year+31.17%USD 21.302021-08-27
Since inception+45.14%USD 19.252021-06-25

GH Research Financials at a Glance

Market Cap

$1.92BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$62.27M

EPS (TTM)

-$0.99

P/E Ratio

-28.30

Dividend

$0.00

Beta (Volatility)

1.08 (Average)

Price

$27.95

Volume

117,667.247

Open

$28.61

Previous Close

$27.94

Daily Range

$27.82 - $28.61

52-Week Range

$11.83 - $31.44

Estimated Earnings Date

Nov 5, 2026

GHRS News

Hands holding some pills from a bottle

5 Best Psychedelic Stocks for 2026 and How to Invest

Keith SpeightsJul 10, 2026

GHRS: Motley Fool Moneyball Superscore

54

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About GH Research

GH Research PLC is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for psychiatric and neurological conditions. The company specializes in 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, particularly for patients with treatment-resistant depression (TRD).

Products and Services
  • GH001: Inhalable 5-MeO-DMT product candidate for TRD
  • GH002: Injectable 5-MeO-DMT candidate in preclinical development
  • GH003: Intranasal 5-MeO-DMT candidate targeting various disorders
Growth Outlook
  • Successful completion of two Phase 1 clinical trials for GH001
  • Expansion into multiple psychiatric and neurological disorders with GH002 and GH003
  • Strong cash position of $345 million as of June 30, 2026
Financial Highlights
  • Net income of -$15.1 million for Q2 2026
  • Operating expenses of $19.5 million in Q2 2026, primarily R&D
  • Cash and short-term investments totaling $362.7 million as of June 30, 2026
GH Research PLC is positioned in the biotechnology sector, focusing on groundbreaking treatments for mental health conditions. The company's lead product, GH001, has shown promise in clinical trials, indicating potential for future market success. With a robust cash reserve, the company is well-equipped to fund ongoing research and development efforts. The financial data reflects significant investment in R&D, which is crucial for advancing its product pipeline. As the company continues to develop its innovative therapies, it may attract interest from investors looking for opportunities in the evolving biopharmaceutical landscape.
AI Generated • Aug 21, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

73

CEO

Villy Valcheva, MD

Website

www.ghres.com

Headquarters

Dublin, DU D02 RY95, IE

GHRS Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-20.86%

Return on Capital

-21.65%

Return on Assets

-16.72%

Earnings Yield

-3.53%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.92BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

68.64M

Volume

117.67K

Avg. Volume

288.10K

Financials (TTM)

Gross Profit

-$268.00K

Operating Income

-$71.44M

EBITDA

-$61.71M

Operating Cash Flow

-$52.39M

Capital Expenditure

-$139.36K

Free Cash Flow

-$52.53M

Cash & ST Invst.

$362.65M

Total Debt

$360.00K

GH Research Performance Analysis

GH Research annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
GH Research sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
GH Research annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.43144.0%
20232023-12-31USD -0.6858.5%
20242024-12-31USD -0.759.5%
20252025-12-31USD -0.795.6%
GH Research sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-53.3%
Q42025-12-31N/A
Q12026-03-31-34.8%
Q22026-06-3025.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.92BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$26.27M

N/A

Employees

73

N/A

Net Income

-$15.15M

-63.1%

EBITDA

-$15.05M

-63.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$362.65M

+24.4%

Total Debt

$360.00K

-44.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$6.00K

-97.9%

Short Term Debt

$354.00K

-2.7%

Return on Assets

-16.72%

N/A

Return on Invested Capital

-19.87%

N/A

Free Cash Flow

-$15.04M

-66.6%

Operating Cash Flow

-$15.02M

-67.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NBTXNanobiotix S.A.
$41.23-8.70%
PVLAPalvella Therapeutics, Inc.
$149.97-0.24%
TYRATyra Biosciences, Inc.
$24.94-4.55%
KURAKura Oncology, Inc.
$12.66-3.95%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$217.55-0.05%
PCGPG&E
$16.60-0.08%
BITOProShares Trust - ProShares Bitcoin ETF
$10.45-0.03%
IRENIren
$35.45-0.13%

Questions About GHRS

What is the current price of GH Research?

GH Research is trading at $27.94 per share.

What is the 52-week range for GH Research?

Over the past 52 weeks, GH Research has traded between $11.83 and $31.44.

How much debt does GH Research have?

As of the most recent reporting period, GH Research reported total debt of $360.00K.

How much cash does GH Research have on hand?

GH Research reported $345.05M in cash and cash equivalents in its most recent financial results.

What is GH Research’s dividend yield?

GH Research does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services